^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

sirexatamab (DKN-01)

i
Other names: DKN-01, LY2812176, LY-2812176, DKN 01, DKN01, LY 2812176
Company:
Eli Lilly, Leap Therap
Drug class:
DKK1 protein inhibitor
Related drugs:
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
05/13/2024
Initiation :
08/29/2023
Primary completion :
01/31/2027
Completion :
01/31/2029
CTNNB1 • AXIN1 • RSPO2 • ZNRF3
|
CTNNB1 mutation
|
Keytruda (pembrolizumab) • sirexatamab (DKN-01)
Phase 2
Leap Therapeutics, Inc.
Active, not recruiting
Last update posted :
01/22/2024
Initiation :
07/29/2020
Primary completion :
06/01/2025
Completion :
12/01/2025
PD-L1 • DKK1
|
5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • leucovorin calcium • sirexatamab (DKN-01)
Phase 1
Leap Therapeutics, Inc.
Completed
Last update posted :
11/01/2023
Initiation :
05/05/2014
Primary completion :
07/19/2019
Completion :
01/11/2021
PD-L1
|
Keytruda (pembrolizumab) • paclitaxel • sirexatamab (DKN-01)
Phase N/A
Leap Therapeutics, Inc.
Available
Last update posted :
09/29/2023
RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3
|
sirexatamab (DKN-01)
Phase 1/2
Johannes Gutenberg University Mainz
Recruiting
Last update posted :
10/22/2020
Initiation :
10/10/2018
Primary completion :
08/31/2021
Completion :
08/31/2022
PD-1
|
sorafenib • sirexatamab (DKN-01)
Phase 2
European Organisation for Research and Treatmen...
Withdrawn
Last update posted :
02/05/2020
Initiation :
12/01/2019
Primary completion :
04/01/2021
Completion :
04/01/2022
HER-2
|
HER-2 positive
|
cisplatin • Tecentriq (atezolizumab) • paclitaxel • sirexatamab (DKN-01)